CG347B
CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research[1][2].
Product Specifications
CAS Number
1598426-03-9
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/cg347b.html
Concentration
10mM
Purity
98.07
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=CN=C(NC2(C3=CC=CC=C3)CC2)N=C1)OCC
Molecular Formula
C16H17N3O2
Molecular Weight
283.33
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Christopher M. YATES. Metalloenzyme inhibitor compounds. WO2018165520A1.|[2]Wang W, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020 Sep 2;19 (1) :134. |[3]Cui J, et al. IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. Cell Death Dis. 2021 May 18;12 (6) :501.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC6
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
